ArticleScientific reports2025
A machine learning model and molecular clusters of epigenetic chromatin regulators in tuberculosis based on bioinformatics and clinical samples.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of chromatin regulators (CRs) in mediating epigenetic changes during tuberculosis (TB) infection remains poorly understood. This study aimed to determine the efficacy of CRs in diagnosing TB and characterizing its heterogeneity. GSE83456 dataset was analyzed to identify differentially expressed CRs (DE-CRs) and immune cell infiltration in patients with TB. Consensus clustering was used to classify patients with TB based on DE-CR expression patterns. The optimal machine learning model was selected from four algorithms (Random Forest (RF), Support Vector Machine (SVM), Generalized Linear Model (GLM), and eXtreme Gradient Boosting (XGB)) to differentiate between the molecular clusters. Validation was performed using an external dataset (GSE152532). Blood samples were collected from healthy individuals and patients with pulmonary TB (PTB) or tuberculous meningitis (TBM). Analysis identified 15 DE-CRs, which were used to stratify patients with TB into two distinct molecular clusters exhibiting divergent immune microenvironment characteristics. The XGB model exhibited superior performance in distinguishing these clusters (area under the receiver operating characteristic curve = 0.965). From this model, a five-gene signature (DHRS9, HIST1H2BK, C16orf74, SLC30A1, and GBP1) was identified. This signature effectively predicted TB subtypes and was significantly associated with active TB (ATB) in an external validation set. Clinically, IFIT3 expression was validated as being significantly elevated in the blood of patients with TB (including PTB and TBM) compared to healthy controls, thereby confirming its potential role as a pan-TB biomarker. Our study revealed that CRs are closely associated with immune infiltration and heterogeneity in TB. We developed a robust XGBoost model based on a five-gene signature for accurate TB subtyping and disease-status assessment. Elevated IFIT3 expression underscores the value of CRs as novel biomarkers for TB diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.